Tau aggregation is known to be a major factor in neurodegeneration and behavioral disorders in patients with tauopathies, including Alzheimer’s disease (Saroja et al., 2022). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.